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Abstract
The tryptophan isomers of the cyclic tetrapeptide CJ-15,208, reported to be a kappa opioid
receptor (KOR) antagonist [Saito, T.; Hirai, H.; Kim, Y. J.; Kojima, Y.; Matsunaga, Y.; Nishida,
H.; Sakakibara, T.; Suga, O.; Sujaku, T.; Kojima, N. J. Antibiot. (Tokyo) 2002, 55, 847–854.],
were synthesized to determine the tryptophan stereochemistry in the natural product. A strategy
was developed to select linear precursor peptides that favor cyclization using molecular modeling,
and optimized cyclization conditions are reported. The optical rotation of the L-Trp isomer is
consistent with that of the natural product. Unexpectedly both isomers exhibit similar nanomolar
affinity for KOR.
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Kappa opioid receptor (KOR) antagonists have demonstrated promising activity in animal
models as antidepressants, anxiolytics, and therapeutics for cocaine and opiate abuse.1 Thus,
there is considerable interest in developing new KOR antagonists as potential therapeutic
agents. Several nonpeptide selective KOR antagonists (i.e., norbinaltorphimine (norBNI),
5′-guanidinonaltrindole (GNTI), and (3R)-7-hydroxy-N-[(1S)-1-[[(3R,4R)-4-(3-
hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-1,2,3,4-tetrahydro-3-
isoquinolinecarboxamide (JDTic)) have been identified and used as pharmacological tools to
study KOR.1a,2 However, all these compounds exhibit exceptionally long antagonist
activity, lasting for weeks to more than a month after a single injection,1a a profile which
could potentially limit their use as therapeutic agents. In contrast, peptide antagonists are
expected to exhibit shorter durations of activity in vivo as a result of metabolism by
proteases.3 While linear peptides are often metabolized too rapidly for use in vivo,
cyclization can increase metabolic stability and improve pharmacokinetic properties.3,4
Head-to-tail cyclic peptides represent a unique class of peptides that exhibit biological
activity at a broad range of targets. A number of cyclic tetrapeptides with diverse biological
activities have been obtained from different natural sources, including the cytotoxic
chlamydocin and immunosuppressant FR 235222 (Fig. 1).5 Constrained cyclic peptides have
substantially fewer degrees of freedom than linear peptides and therefore may provide
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valuable information about the spatial requirements necessary for the interaction of ligand
functional groups with the target binding site.
Saito et al.6 reported the isolation and characterization of the cyclic tetrapeptide CJ-15,208
(Fig. 2) from the fermentation broth of the fungus Ctenomyces serratus ATCC 15502. In
binding assays this peptide was reported to preferentially bind to KOR with an IC50 value of
47 nM and antagonized the KOR agonist asimadoline in the electrically-stimulated rabbit
vas deferens.6 Thus, this peptide provides a novel lead for the development of new KOR
antagonists.
Saito et al. elucidated the structure of CJ-15,208 using high resolution fast atom
bombardment mass spectrometry and NMR to establish the sequence and cyclic structure of
this peptide.6 This cyclic tetrapeptide consists of a proline, a tryptophan, and two
phenylalanine residues (Fig. 2). While amino acid analysis and HPLC of chiral derivatives
established the identity and stereochemistry of the Pro and Phe residues, the stereochemistry
of the Trp residue was not determined due to destruction during acid hydrolysis.6 While
there is a brief reference to the L-Trp isomer in a conference proceeding,7 no details on the
synthesis were provided nor was evidence presented to establish whether this isomer was the
natural product. Therefore, we undertook the synthesis of both isomers of CJ-15,208 varying
in the stereochemistry of the Trp residue (Fig. 2) to conclusively identify the natural product
and to develop synthetic schemes that may be applied to the synthesis of future analogs.8
Difficulties have often been encountered during the synthesis of cyclic tetrapeptides due to
the constrained 12-membered ring structure of the product. Most cyclic tetrapeptide natural
products contain at least one turn-inducing residue such as Pro, an N-substituted amino acid,
Gly, or Aib (α-aminoisobutyric acid) that favors a folded conformation and is essential for
cyclization.9 The cyclization reaction still often leads to the formation of the cyclic
octapeptide, which in some cases is the predominant product.10 The amino acid sequence of
the linear precursor and the method of activation of the carboxy terminus also have
significant influence on the results of the cyclization reaction.10a,11
Initially the syntheses of the isomers of CJ-15,208 were attempted using a similar strategy to
that described for trapoxin B12 based on the similarity in backbone structure. The cyclization
reaction was performed using the linear sequences Phe-Trp-Phe-D-Pro and Phe-D-Trp-Phe-D-
Pro with D-proline at the C-terminus. Despite a variety of attempts using different reaction
conditions and coupling reagents, including the pentafluorophenyl ester methodology
reported by Schmidt et al.,9a,11b the desired cyclic tetrapeptides were not observed.
The sequence of the precursor linear peptide can have a marked influence on the success of
the cyclization reaction.11a In cyclic tetrapeptides such as CJ-15,208 there are four different
linear sequences that can be used to attempt cyclization. However, not all of the linear
sequences may give the desired cyclic tetrapeptide in high yield, with some sequences
yielding little or no desired product.11a,b Also which linear sequences will successfully
cyclize differs for different cyclic tetrapeptides.11a,b
Molecular modeling and conformational analysis can aid in identifying linear precursor
peptides that may adopt conformations that can undergo cyclization.13 Therefore we utilized
molecular modeling to choose linear sequences for cyclization to increase the probability of
cyclic tetrapeptide formation. Thus, we initiated a molecular modeling study with the four
possible linear precursors for both tryptophan isomers of CJ-15,208 (Table 1).14
The results of the molecular modeling suggested which linear sequences were likely to be
compatible with cyclization. The conformation of the linear precursor peptide plays a very
important role in successful cyclizations, and intramolecular hydrogen bonds can stabilize a
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folded conformation that is favorable for cyclization.4 Analysis of the linear sequence Phe-
Trp-Phe-D-Pro with D-proline at the C-terminus suggested that it preferentially existed in an
extended conformation with a distance of about 11 Å between the amino and carboxy
termini (Table 1), which is consistent with our inability to obtain the cyclic tetrapeptide from
this linear precursor. In contrast, analysis of the linear peptides with proline at the Ci+1 or
Ci+2 position resulted in folded conformations with the amino and carboxy termini in closer
proximity. A similar analysis of the possible linear sequences containing D-Trp was also
performed. Based on this analysis cyclization of the linear sequences Phe-D-Pro-Phe-Trp for
the L-Trp peptide and D-Trp-Phe-D-Pro-Phe or Phe-D-Pro-Phe-D-Trp for the D-Trp isomer was
expected to yield the required cyclic tetrapeptides.
The linear peptide precursors were synthesized on the 2-chlorotrityl resin (Scheme 1).
Attachment of the first amino acid to the resin was performed using a twofold excess of
amino acid and DIEA (N,N-diisopropylethylamine) (Scheme 1).15 The synthesis of the
linear peptides was performed using Fmoc-protected amino acids and standard coupling and
deprotection protocols. Previously Mou and Singh reported that the protection of the indole
nitrogen of Trp in the precursor of apicidin was necessary for the successful cyclization
using the pentafluorophenyl ester method.11c Therefore the indole nitrogen of the Trp
residue in our linear precursor peptides was initially protected with the Boc-protecting
group.8 This proved unnecessary using the cyclization conditions described below, however,
and the cyclic peptides were subsequently synthesized using Fmoc-Trp without side chain
protection (Scheme 1). The crude linear peptides were ≥98% pure by analytical HLPC
following cleavage from the resin with 1% trifluoroacetic acid (TFA) in dichloromethane
(DCM).15
The cyclization of the linear peptide Phe-D-Pro-Phe-Trp was performed in solution. The
conditions used for the cyclization had a marked influence on the results of this reaction, in
terms of the formation of the dimeric cyclic octapeptide versus the desired cyclic
tetrapeptide. Highly dilute conditions minimize the formation of the cyclic octapeptide.12
Also the use of the azabenzotriazole-derived uronium reagent HATU (2-(1H-7-
azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) has been reported
to facilitate a difficult cyclization and decrease cyclodimerization compared to
benzotriazole-derived coupling agents,10a most likely due to neighboring group assistance
by the ring nitrogen. When the cyclization of Phe-D-Pro-Phe-Trp was performed in DCM/
MeCN, however, even in dilute solution with slow addition of the linear peptide, the cyclic
octapeptide was obtained in addition to the desired cyclic tetrapeptide. The rate of addition
of Phe-D-Pro-Phe-Trp also affected the yields of the cyclic tetrapeptide versus cyclic
octapeptide; even in dilute solution the rapid addition of the linear peptide resulted in the
cyclic octapeptide predominating, even when DMF (N,N-dimethylformamide) was used as
the solvent.16 Based on these results and procedures reported previously for the other cyclic
tetrapeptides,10a,12 optimized conditions for the cyclization were developed which involved
the slow addition of the linear peptide in DMF over 12 h to a dilute solution of HATU and
DIEA in DMF.17 Mass spectrometry and HPLC analysis of the isolated product indicated
the formation of the desired cyclic tetrapeptide cyclo[Phe-D-Pro-Phe-Trp]18 with minimum
formation of the cyclic octapeptide (<5%) under these conditions.
The same optimized conditions were also used to cyclize D-Trp-Phe-D-Pro-Phe to give the D-
Trp isomer of CJ-15,208, which was analyzed by mass spectrometry and HPLC.19 In
contrast to the L-Trp peptide, cyclization of D-Trp-Phe-D-Pro-Phe yielded minimal cyclic
octapeptide even under conditions where the linear L-Trp precursor yielded almost
exclusively the cyclic dimer. Thus the second D-amino acid in the D-Trp peptide facilitated
the folding of the linear precursor into a conformation that favors cyclization to give the
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cyclic tetrapeptide, making the synthesis of this cyclic peptide more straight forward than
the L-Trp isomer.
One concern during head-to-tail cyclizations is epimerization of the C-terminal residue.
Azabenzotriazole reagents such as HATU minimize epimerization of the C-terminal residue
of peptides during activation and coupling.20 The L-Trp and D-Trp cyclic tetrapeptides had
very different retention times on HPLC (tR = 26.0 and 35.5 min, respectively), and the D-Trp
peptide was not detected during cyclization of Phe-D-Pro-Phe-Trp, suggesting minimum
epimerization of the C-terminal residue that occurred during cyclization under the conditions
described above.
The optical rotation of the L-Trp cyclic tetrapeptide closely matched the reported value for
the natural product (αD = −63.6° (c 0.05, DMSO), lit.6 (αD = −64.0° (c 0.05, DMSO)),
while the optical rotation of the isomer containing D-Trp had the opposite sign (αD = +19.8°
(c 0.05, DMSO)). Surprisingly both cyclic tetrapeptides exhibited nanomolar affinity for
KOR (Ki (± SEM) = 21.2 ± 5.6 and 46.9 ± 16.1 nM for the L-Trp and D-Trp isomers,
respectively), in competition radioligand-binding assays using mouse brain membranes and
[3H]U69,593 as the radioligand). These results are similar to those recently reported for the
D-Trp isomer of CJ-15,208 by Dolle et al.21
In conclusion, we successfully synthesized the two isomers of the cyclic tetrapeptide
CJ-15,208 containing L- and D-tryptophan. Using the molecular modeling approach described
here appropriate linear sequences were chosen for cyclization. The synthesis of the L-Trp
isomer still proved challenging, however, because of the tendency of the linear precursor to
dimerize during cyclization. Optimized cyclization conditions were identified that
minimized the formation of the cyclic octapeptide and maximized the yield of the desired
cyclic tetrapeptide. The optical rotation of the L-Trp isomer agrees with the optical rotation
reported for the natural product CJ-15,208.6 Unexpectedly, both compounds exhibit
nanomolar affinity for KOR and thus can serve as excellent leads for further structural
modification. Such studies are currently underway in our laboratory. Cyclization using a
linear peptide that is preselected based on molecular modeling as described here will assist
in the synthesis of analogues of these and other cyclic tetrapeptides.
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Cyclic tetrapeptide natural products.
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Cyclic tetrapeptide natural product CJ-15,208.
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Synthesis of the cyclic tetrapeptide containing L-Trp.
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Table 1
Analysis of the conformations of the linear peptides by molecular modeling
Linear sequence Hydrogen bonds Conformationa Distanceb (Å)
L-Trp isomer
Phe-Trp-Phe-D-Pro — Extended 11.5
Trp-Phe-D-Pro-Phe 2 γ-Turn 6.5
Phe-D-Pro-Phe-Trp 1 β-Turn 3.4
D-Pro-Phe-Trp-Phe — Extended 11.9
D-Trp isomer
Phe-D-Trp-Phe-D-Pro — Extended 10.4
D-Trp-Phe-D-Pro-Phe 2 γ-Turn 2.9
Phe-D-Pro-Phe-D-Trp 2 γ-Turn 3.1
D-Pro-Phe-D-Trp-Phe — Extended 11.6
a
Preliminary assignment based on hydrogen bonding patterns.
b
The distance was measured from the carboxy terminal carbonyl carbon to the amino terminal nitrogen.
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